Clinical trials for Tolerability

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44380 clinical trials with a EudraCT protocol, of which 7392 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (14,043)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

14,043 result(s) found for: Tolerability. Displaying page 151 of 703.

EudraCT Number: 2005-003475-20

Sponsor Protocol Number: S1543016

Start Date*: 2006-05-25

Sponsor Name:Solvay Pharmaceuticals, Inc

Full Title: A Randomized, Double-Blind, Placebo-Controlled, Efficacy, Safety and Tolerability Study of Bifeprunox in the Treatment of Elderly Subjects with Psychosis and Behavioural Disturbances Associated wit...

Medical condition: Dementia of the Alzheimer's type (DSM-IV TR) code 294.11

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:			10012271

Population Age: Elderly

Gender: Male, Female

Trial protocol: EE (Prematurely Ended) CZ (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2007-002090-31

Sponsor Protocol Number: CAT-354-0603

Start Date*: 2007-09-26

Sponsor Name:MedImmune Limited

Full Title: A double-blind, placebo-controlled parallel-group study to assess the efficacy, safety, and tolerability of CAT-354

Medical condition: Asthma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8.1		10003553	Asthma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended)

Trial results: View results

EudraCT Number: 2007-005088-82

Sponsor Protocol Number: CAFQ056A2204

Start Date*: 2008-05-15

Sponsor Name:Novartis Pharma Services AG

Full Title: A multi-centre, randomized, double-blind, placebo-controlled, two-period, crossover proof-of-concept study in patients with Fragile X Syndrome to assess the efficacy, safety and tolerability of mul...

Medical condition: Fragile X Syndrome

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10017324	Fragile X syndrome	PT

Population Age: Adults

Gender: Male

Trial protocol: FR (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2011-004002-25

Sponsor Protocol Number: B1621007

Start Date*: 2012-01-12

Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017

Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-04937319 AND SITAGLIPTIN ON GLYCEMIC CONTROL IN ADULT PATIENTS WI...

Medical condition: Type 2 Diabetes Mellitus (T2DM)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.0	10027433 - Metabolism and nutrition disorders	10045242	Type II diabetes mellitus	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: HU (Completed) SK (Completed)

Trial results: View results

EudraCT Number: 2011-000250-28

Sponsor Protocol Number: 905-CL-079

Start Date*: 2011-11-15

Sponsor Name:Astellas Pharma Europe B.V.

Full Title: A Multicenter, Open-label, Single-dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Subjects from 5 to less than 18 years of age with...

Medical condition: Neurogenic Detrusor Overactivity (NDO)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10038359 - Renal and urinary disorders	10012547	Detrusor hyperreflexia	LLT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: BE (Completed) GB (Completed) DK (Completed)

Trial results: View results

EudraCT Number: 2012-000128-16

Sponsor Protocol Number: 2011-003

Start Date*: 2012-07-30

Sponsor Name:Onyx Therapeutics, Inc.

Full Title: A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma

Medical condition: Multiple myeloma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	19.0	100000004864	10028228	Multiple myeloma	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Completed) GB (Completed) HU (Completed) DE (Completed) IT (Completed) ES (Completed) SK (Completed) GR (Completed) CZ (Completed) AT (Completed) BG (Completed) PL (Completed)

Trial results: View results

EudraCT Number: 2005-005675-15

Sponsor Protocol Number: DIL-UBI-DEX-CLOII/2003/003/PT

Start Date*: 2008-10-08

Sponsor Name:Tecnimede, Sociedade Técnico-Medicinal S.A.

Full Title: Randomized, multicenter, placebo-controlled, single blind study to assess the efficacy and tolerability of a combination of a cream containing ubidecarenone, dexpanthenol and chlorohexidine and a p...

Medical condition: Cronic Anal fissure (CAF) The underlying pathogenesis of chronic anal fissure involves initial local trauma (generally caused by hard stools), resulting in a wound, internal anal sphincter spasm an...

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	16.0	100000004856	10071195	Chronic anal fissure	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: PT (Completed) CZ (Completed) ES (Completed)

Trial results: View results

EudraCT Number: 2011-006294-26

Sponsor Protocol Number: 021101

Start Date*: 2013-04-07

Sponsor Name:Baxter Innovations GmbH

Full Title: A Phase 3, Prospective, Open-label, Randomized Study to Evaluate Safety and Efficacy of Recombinant Activated FVII BI (rFVIIa BI) in the Treatment of Acute Bleeding Episodes per an On-demand Regime...

Medical condition: Hemophilia A or B with FVIII or FIX inhibitors

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.1	100000004850	10053751	Hemophilia A with anti factor VIII	LLT
	14.1	100000004850	10053752	Hemophilia B with anti factor IX	LLT

Population Age: Adolescents, Under 18, Adults

Gender: Male

Trial protocol: ES (Completed) BE (Completed) PL (Completed)

Trial results: View results

EudraCT Number: 2012-004786-40

Sponsor Protocol Number: PB-102-F01

Start Date*: 2013-05-10

Sponsor Name:Protalix Ltd.

Full Title: A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks ...

Medical condition: Fabry disease

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.0	10010331 - Congenital, familial and genetic disorders	10016016	Fabry's disease	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed) ES (Completed)

Trial results: View results

EudraCT Number: 2016-000821-37

Sponsor Protocol Number: GS-US-416-2124

Start Date*: 2017-02-06

Sponsor Name:Gilead Sciences, Inc.

Full Title: A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination with Prednisolone versus Prednisolone Alone in Subjects with Severe Alcoholic H...

Medical condition: Alcoholic Hepatitis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	19.1	100000004871	10001624	Alcoholic hepatitis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: AT (Completed) BE (Completed) GB (Completed)

Trial results: View results

EudraCT Number: 2016-001496-75

Sponsor Protocol Number: GS-US-379-1582

Start Date*: 2016-12-20

Sponsor Name:Gilead Sciences, Inc.

Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy of GS-9876 in Subjects with Active Rheumatoid Arthritis on...

Medical condition: Rheumatoid Arthritis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	19.0	10028395 - Musculoskeletal and connective tissue disorders	10039073	Rheumatoid arthritis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: CZ (Completed) PL (Completed)

Trial results: View results

EudraCT Number: 2016-003417-95

Sponsor Protocol Number: 201247

Start Date*: 2017-01-13

Sponsor Name:GlaxoSmithKline Research & Development Ltd

Full Title: A multi-centre, randomized, double-blind (sponsor open), placebo controlled, repeat-dose, proof of mechanism study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and explo...

Medical condition: Systemic sclerosis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	19.0	10028395 - Musculoskeletal and connective tissue disorders	10042953	Systemic sclerosis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed) NL (Completed)

Trial results: View results

EudraCT Number: 2016-003585-11

Sponsor Protocol Number: VX16-659-101

Start Date*: 2017-09-01

Sponsor Name:Vertex Pharmaceuticals Incorporated

Full Title: A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis

Medical condition: Cystic fibrosis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10010331 - Congenital, familial and genetic disorders	10011762	Cystic fibrosis	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: IE (Completed) GB (Completed)

Trial results: View results

EudraCT Number: 2015-005021-39

Sponsor Protocol Number: CAIN457F2308

Start Date*: 2016-08-04

Sponsor Name:Novartis Pharma Services AG

Full Title: A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab in prefilled syringes, to compare efficacy at 16 weeks with placebo and to assess safety and ...

Medical condition: Ankylosing Spondyloarthritis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10028395 - Musculoskeletal and connective tissue disorders	10002556	Ankylosing spondylitis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed) CZ (Completed)

Trial results: View results

EudraCT Number: 2005-005980-27

Sponsor Protocol Number: NK-104-308

Start Date*: 2006-05-04

Sponsor Name:Kowa Research Europe Ltd.

Full Title: OPEN-LABEL, LONG-TERM ( ≥ 1 YEAR) EXTENSION STUDY OF PITAVASTATIN 2 MG AND 4 MG QD IN ELDERLY PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA

Medical condition: Patients with Primary Hypercholesterolemia or Combined Dyslipidemia

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8.1		10020604		LLT

Population Age: Elderly

Gender: Male, Female

Trial protocol: GB (Completed) DK (Completed) DE (Completed)

Trial results: View results

EudraCT Number: 2007-005721-30

Sponsor Protocol Number: 161HF201

Start Date*: 2009-10-26

Sponsor Name:Biogen Idec

Full Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral Tonapofylline in Patients with Heart Failure and Renal Insufficiency

Medical condition: Heart Failure and Renal Insufficiency.

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10038474	Renal insufficiency	LLT
	9.1		10019279	Heart failure	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended)

Trial results: View results

EudraCT Number: 2013-002287-11

Sponsor Protocol Number: BAY1021189/15371

Start Date*: 2013-12-12

Sponsor Name:Bayer HealthCare AG

Full Title: A randomized parallel-group, placebo-controlled, double-blind, multi-center dose finding phase II trial exploring the pharmacodynamic effects, safety and tolerability, and pharmacokinetics of four ...

Medical condition: Heart failure

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.1	100000004849	10008908	Chronic heart failure	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: CZ (Completed) IT (Completed) AT (Completed) BE (Completed) SE (Completed) DK (Completed) DE (Completed) ES (Completed) NL (Completed) HU (Completed) BG (Completed) GR (Completed)

Trial results: View results

EudraCT Number: 2013-002288-25

Sponsor Protocol Number: BAY1021189/15829

Start Date*: 2013-12-12

Sponsor Name:Bayer HealthCare AG

Medical condition: Heart failure

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	18.0	100000004849	10008908	Chronic heart failure	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: CZ (Completed) IT (Completed) AT (Completed) BE (Completed) SE (Completed) DK (Completed) NL (Completed) ES (Completed) HU (Completed) BG (Completed) PT (Completed) GR (Completed)

Trial results: View results

EudraCT Number: 2014-005619-18

Sponsor Protocol Number: Calcichew-4001

Start Date*: 2015-05-05

Sponsor Name:Takeda Development Centre Europe Ltd.

Full Title: A Randomized, Open-Label, 2-Way Cross-over, Phase 4 Study to Evaluate Subject Preference and Acceptability of a New Formulation of Calcichew D3 in Adult Patients Eligible for Calcium and Vitamin D ...

Medical condition: Prevention and treatment of vitamin D and calcium deficiency and adjunct to specific osteoporosis treatment of patients who are at risk of vitamin D and calcium deficiency

Disease:	Version	SOC Term	Classification Code	Term	Level
	18.0	100000004859	10031289	Osteoporosis, unspecified	LLT
	18.0	10027433 - Metabolism and nutrition disorders	10027433	Metabolism and nutrition disorders	SOC

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed) DE (Completed)

Trial results: View results

EudraCT Number: 2014-002208-26	Sponsor Protocol Number: MK-8342B-062	Start Date*: 2015-10-23
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.
Full Title: A Phase 3, randomized, active-comparator controlled clinical trial to study the contraceptive efficacy and safety of the MK-8342B (etonogestrel + 17β-estradiol) vaginal ring and the levonorgestrel-...
Medical condition: Contraception
Disease:
Population Age: Adults		Gender: Female
Trial protocol: NO (Completed) SE (Completed) DE (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended) AT (Completed) ES (Completed) NL (Completed) HU (Completed) PL (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended)
Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Tue Feb 10 12:37:58 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA